GSK PLC Sponsored ADR $GSK Position Increased by Clark Capital Management Group Inc.

Key Points

• Clark Capital Management Group Inc. significantly increased its stake in GSK PLC, raising ownership by 138.2% to a total of 1,565,735 shares, valued at approximately $60.66 million.
• GSK reported positive earnings results, with $1.23 EPS for the quarter, exceeding the consensus estimate of $1.12, alongside a revenue of $10.64 billion.
• The firm announced a quarterly dividend of $0.4206, translating to an annualized yield of 4.3% and a payout ratio of 77.78%.

Clark Capital Management Group Inc. raised its position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 138.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,565,735 shares of the pharmaceutical company's stock after purchasing an additional 908,284 shares during the quarter. Clark Capital Management Group Inc. owned about 0.08% of GSK worth $60,657,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC boosted its stake in GSK by 222.2% during the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company's stock valued at $26,000 after purchasing an additional 460 shares in the last quarter. Costello Asset Management INC bought a new stake in shares of GSK during the 1st quarter worth $31,000. Richardson Financial Services Inc. boosted its stake in shares of GSK by 127.9% during the 1st quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company's stock worth $33,000 after acquiring an additional 472 shares in the last quarter. Olde Wealth Management LLC bought a new stake in shares of GSK during the 1st quarter worth $36,000. Finally, Cary Street Partners Investment Advisory LLC boosted its stake in shares of GSK by 525.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 1,014 shares of the pharmaceutical company's stock worth $39,000 after acquiring an additional 852 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

GSK Stock Up 2.2%

Shares of GSK traded up $0.90 during mid-day trading on Tuesday, reaching $40.95. The company's stock had a trading volume of 2,471,436 shares, compared to its average volume of 5,059,377. The business has a fifty day moving average of $38.55 and a 200 day moving average of $38.38. The company has a market cap of $83.40 billion, a price-to-earnings ratio of 18.95, a price-to-earnings-growth ratio of 2.03 and a beta of 0.53. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $44.19. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The company had revenue of $10.64 billion during the quarter, compared to analyst estimates of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be issued a $0.4206 dividend. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.1%. GSK's dividend payout ratio is presently 77.78%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on GSK. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen raised GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and a consensus price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.